Capmatinib is a MET inhibitor specifically made for NSCLC with a MET exon 14 skip mutation. It works by focusing on the MET kinase to stop cancer growth. You’ve got two tablet strengths to choose from: 150 mg and 200 mg.
The usual dose is 400 mg, twice a day, and you can take it with or without eating. Each bottle holds 60 tablets.
